Letters to the Editor
Measurement of ethylene glycol In biological specimens I must rebut the arfuments put forward by Flanagan et al, in their reply to my letter:~The authors have gone to great lengths to try and demonstrate that my method of sample preparation for performing serum ethylene glycoldeterminations) is unnecessarily complicated. In fact, the opposite is true. The modifications I have introduced were in response to problems I encountered during efforts to introduce the method of Porter and Aunsakul" into routine service. Each procedure has a centrifugation step and my method uses only two more reagent additions than that of Flanagan et al? One of these (the neutralisation step) is optional in packed column GC analysis. Thus, there is no important difference in the complexity of reagent addition in the two methods.
The main temporal difference in sample preparation between the two methods isin the derivatisation. I have found (through a time course study) that a 10-15 min reaction time is necessary to ensure complete boronation of the diols in the sample. Oncolumn boronation was inadequate. In the final paragraph of their own paper, in which Flanagan et al. diseuss the application of their method. they state 'In all cases. however. we would recommend the analysis of a plasma blank prior to an unknown sample because of the pos. sibility of carry-over'." It is obvious that the problem of unreacted diols carrying over into the next chromatogram is significant. Quite clearly. taking 15 min to derivatise all of the controls and unknowns simultaneously is preferable to analysing blanks between the samples and perhaps also the controls in order to eliminate the possibility of carry-over.
On the matter of column clean-up after the complete batch has been analysed, Flanagan et al, pointed out that in mr method the clean-up procedure took 15-20 min. The inference appears to be that this is a time-consumingprocedure. As I stated in my paper, however, instrument time is 15-20 min. but technologist hands-on time is only 3 min." Given that ethylene glycol tests arc not requested several times a day, technologist time is fundamentally more valuable than instrument time. This maintenance procedure is hardly either tedious or labourintensive.
I do hope that readers now have a more balanced viewof this matter. I thank them for their indulgence. Editor's note. This correspondence is now closed.
The oral glucose tolerance test_ assessment of the quality of Its performance
The article by Wiener (Ann Clin Biochem 1987; 24: 440-6) assessing the quality of performance and interpretation of the oral glucose tolerance test (OGTI) was timely. and re-emphasised the recommendations of the World Health Organisation I. 2 to standardise on the 75 g oral load. Currently. 82% of the participating laboratories would appear to follow these recommendations.
The OGTI is one of the oldest and most frequently used dynamic tests undertaken in Clinical Biochemistry Departments. Therefore, it is surprising to find disagreement regarding the basic quantity of glucose given as part of an OGTI. We have difficulty in accepting the suggestions of Wiener" 4 to use 50 or ?5 g of glucose monohydrate (C6HI206.H20). as this IS only equivalent to 45 or 67·5 g of glucose anhydrate. We prefer the recommendations of King et al. s to standardise on 50 or 75 g or glucose anhydrate (C. . . .H I2 0 . . . .). or an equivalent quantity of glucose monohydrate i.e. 55·0 or 83·5 g, respectively.
It is accepte? that small variations in the quantity of glucose given as part of an OGTI are unlikely to produce significant variations in blood glucose levels, but it would seem sensible to define more precisely the quantity of glucose given as part of an OGTI. This is particularly important when the results obtained followingan OGTI can have such profound long-term implications for the patient. Future publications from National and International bodies must contain precise details on the degree of hydration of the glucose used in their recommendations on the 75 g OGTI. STANJ A simple side-room test to screen for microalbuminaria in diabetes mellitus
The paper by BW Hodgson and GF Watts, 'A simple side-room test to screen for microalbuminuria in diabetes mellitus' (Ann Clin Biochem 1987; 24: 581-4) mentions our kit for this purpose (AlbuScreen, which has recently been renamed AlbuSure).
It states that our kit is 'said to have a longer shelf-life' than the reagents described in the paper and that 'it also awaits clinical evaluation'.
It is disappointing that the authors did not aks CLS for evidence, since we would have provided proof of our shelf-life which is at least 50 times 'longer than their inconveniently short 4 days. Also we would have referred them to numerous external triallists who have completed clinical evaluations during 1986.
It is also regrettable that our kit may be thought similar to the reported method, which cannot be used as a primary screening test because of prozone inhibition. The CLS A1buSure kit uses HSA-coated latex instead of antibody-coating. Consequently, agglutination indicates low levels of urinary albumin and microalbuminuria inhibits agglutination. Thus, all proteinuric samples are detected by AlbuSure. Furthermore, the inhibition mode makes the test more fail-safe than a direct agglutination.
We would like all these facts to be considered together with the authors' observations about cost of kit versus home-made reagents.
JOHN W SPEIGHT Marketing Manager, Cambridge Life Sciences pic, Science Park, Milton Road, Cambridge CB44EN
The development of sensitive latex agglutination tests for urinary albumin is a welcome addition to those investigations currently being used to monitor diabetes. The aim, in developing such tests, should be to provide a first line screen for albuminuria, the analytical sensitivity exceeding that of the stick tests currently in use.
Hodgson and Watts· describe a simple and apparently robust, in-house latex agglutination test for urinary albumin with a detection limit of 15 mg/L. However, this test cannot be used as a primary screen due to its susceptibility to prozone effects, Albustix remaining as the first line test in the author's laboratory. Such an approach to development offers no significant advance over a previously described test. 2 AlbuScreen, now renamed AlbuSure (Cambridge Life Sciences, Cambridge, UK) has been evaluated in this laboratory. 3 This equally simple test does not suffer from prozone effects, its elegant design being independent of the presence of excess antigen, albumin.
This product has been used for nearly 2 years as the primary on site screen for proteinuria in our diabetic clinic and found to be entirely satisfactory. The price per test is not exorbitant and must be offset against immediate availability and guaranteed calibration.
